X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1003) 1003
Paper (432) 432
Publication (299) 299
Report (189) 189
Book / eBook (26) 26
Data Set (5) 5
Book Chapter (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cern lhc coll (612) 612
experimental results (587) 587
experiment (489) 489
p p: scattering (483) 483
p p: colliding beams (436) 436
physics (423) 423
cms (406) 406
particle physics (406) 406
high energy physics - experiment (404) 404
13000 gev-cms (372) 372
high energy physics (333) 333
physics - high energy physics - experiment (307) 307
hep (305) 305
phenomenology (221) 221
nuclear experiment (206) 206
ex (205) 205
physics of elementary particles and fields (203) 203
scattering [p p] (185) 185
colliding beams [p p] (171) 171
background (169) 169
hadron-hadron scattering (133) 133
index medicus (133) 133
8000 gev-cms (126) 126
nuclear physics (117) 117
transverse momentum: missing-energy (106) 106
channel cross section: upper limit (101) 101
cern lab (100) 100
humans (100) 100
supersymmetry (99) 99
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (98) 98
mass dependence (95) 95
male (92) 92
final state:jet lepton (90) 90
nucl (89) 89
female (87) 87
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (75) 75
particle physics - experiment (74) 74
transverse momentum dependence (73) 73
bottom: particle identification (69) 69
data analysis method (68) 68
jet: bottom (67) 67
transverse momentum (67) 67
114 physical sciences (64) 64
channel cross section: branching ratio: upper limit (64) 64
kinematics (62) 62
physics, particles & fields (62) 62
top: pair production (62) 62
muon: pair production (61) 61
higgs particle: hadroproduction (57) 57
z0: leptonic decay (56) 56
heavy ion: scattering (55) 55
middle aged (54) 54
animals (52) 52
astrophysics (52) 52
final state:jet dilepton (51) 51
aged (50) 50
lead (50) 50
rapidity (50) 50
bottom: pair production (49) 49
channel cross section: measured (49) 49
mass spectrum: (49) 49
rapidity dependence (48) 48
beyond standard model (47) 47
hep-ex (47) 47
quantum chromodynamics: perturbation theory (45) 45
squark: pair production (45) 45
electroweak interaction (43) 43
analysis (42) 42
final state:jet (42) 42
jet: transverse momentum (42) 42
mass: lower limit (42) 42
adult (41) 41
narrow resonance (40) 40
upper limit [channel cross section] (40) 40
new physics: search for (39) 39
sensitivity (39) 39
tau: pair production (39) 39
w: leptonic decay (39) 39
gravitation (38) 38
nuclear and particle physics. atomic energy. radioactivity (38) 38
numerical calculations: monte carlo (38) 38
structure (38) 38
differential cross section: measured (37) 37
higgs particle: hadronic decay (37) 37
astronomy & astrophysics (36) 36
mice (36) 36
missing-energy [transverse momentum] (36) 36
nuclear and high energy physics (36) 36
transplantation (36) 36
gluino: pair production (35) 35
jet lepton (35) 35
jet: multiplicity (35) 35
signature (35) 35
gluino: mass: lower limit (34) 34
mortality (34) 34
high energy astrophysical phenomena (33) 33
higher-order: 1 (33) 33
immunology (33) 33
physical sciences (33) 33
resonance: production (33) 33
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
UTL at Downsview - May be requested (3) 3
UofT at Mississauga - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Criminology - Stacks (1) 1
Gerstein Science - Stacks (1) 1
Pontifical Inst. Mediaeval Studies - Library use only (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Victoria University CRRS - Library use only (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal Article
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2014, Volume 28, Issue 1, pp. 43 - 54
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2007, Volume 50, Issue 25, pp. 2375 - 2382
Journal Article